Ignite Creation Date:
2025-12-24 @ 3:51 PM
Ignite Modification Date:
2026-01-23 @ 2:05 PM
Study NCT ID:
NCT06614192
Status:
RECRUITING
Last Update Posted:
2025-08-26
First Post:
2024-09-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015179', 'term': 'Colorectal Neoplasms'}], 'ancestors': [{'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000613803', 'term': 'trifluridine tipiracil drug combination'}, {'id': 'D000068258', 'term': 'Bevacizumab'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 460}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-11-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-08', 'completionDateStruct': {'date': '2028-10', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-08-22', 'studyFirstSubmitDate': '2024-09-25', 'studyFirstSubmitQcDate': '2024-09-25', 'lastUpdatePostDateStruct': {'date': '2025-08-26', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2024-09-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-10', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Stage 1: Percentage of Participants with Adverse Events (AE)s', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'An AE is defined as any untoward medical occurrence, inappropriate patient management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational drug.'}, {'measure': 'Stage 1: Percentage of Participants with Clinically Significant Vital Sign Measurements as Assessed by the Investigator', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'Vital signs are defined as determinations of systolic and diastolic blood pressure, pulse rate, respiratory rate, oxygen saturation (SpO2), and body temperature will be obtained at visits.'}, {'measure': 'Stage 1: Percentage of Participants with Clinically Significant Electrocardiograms (ECGs) Findings as Assessed by the Investigator', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'Percentage of participants with clinically significant ECGs findings as assessed by the investigator.'}, {'measure': 'Stage 1: Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, Hematology, Coagulation, and Urinalysis) as Assessed by the Investigator', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'Percentage of participants with clinically significant laboratory values (hematology, chemistry, coagulation, and urinalysis) as assessed by the investigator.'}, {'measure': 'Stage 1 and Stage 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'OR is defined as confirmed complete response (CR) or confirmed partial response (PR) as assessed by BICR per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.'}, {'measure': 'Stage 2: Overall Survival (OS)', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'OS is defined as the time from randomization to the event of death from any cause.'}], 'secondaryOutcomes': [{'measure': 'Stage 1 and Stage 2: Progression Free Survival (PFS) as Assessed by BICR', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'PFS is defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by BICR or death from any cause, whichever occurs earlier.'}, {'measure': 'Stage 1: OS', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'OS is defined as the time from randomization to the event of death from any cause'}, {'measure': 'Stage 1 and Stage 2: Duration of Response (DOR) as Assessed by BICR', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by BICR or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR.'}, {'measure': 'Stage 1 and Stage 2: Disease Control (DC) as Assessed by BICR', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'DC is defined as best overall response of confirmed CR or confirmed PR, or stable disease (SD) based on RECIST, version 1.1 as determined by BICR.'}, {'measure': 'Stage 1 and Stage 2: OR as Assessed by Investigator', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'OR is defined as confirmed CR or confirmed PR as assessed by investigator per RECIST, version 1.1.'}, {'measure': 'Stage 1 and Stage 2: PFS as Assessed by Investigator', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'PFS is defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by investigator or death from any cause, whichever occurs earlier.'}, {'measure': 'Stage 1 and Stage 2: DOR as Assessed by Investigator', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by BICR or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR.'}, {'measure': 'Stage 1: Maximum Observed Serum (or Plasma, for Payload) Concentration (Cmax) for Telisotuzumab Adizutecan', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'Maximum observed serum (or plasma, for payload) concentration for telisotuzumab adizutecan.'}, {'measure': 'Stage 1: Time to Cmax (Tmax) for Telisotuzumab Adizutecan', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'Time to Cmax for telisotuzumab adizutecan.'}, {'measure': 'Stage 1: Terminal Elimination Half-Life (t1/2) for Telisotuzumab Adizutecan', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'Terminal elimination half-life for telisotuzumab adizutecan.'}, {'measure': 'Stage 1: Area Under the Serum (or Plasma, for Payload) Concentration Versus Time Curve (AUC) for Telisotuzumab Adizutecan', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'Area under the serum (or plasma, for payload) concentration versus time curve will be determined using noncompartmental methods for total antibody for telisotuzumab adizutecan.'}, {'measure': 'Stage 1: Antibody Drug Conjugate (ADC) for Telisotuzumab Adizutecan', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'Antibody drug conjugate for telisotuzumab adizutecan.'}, {'measure': 'Stage 1: Unconjugated Topoisomerase 1 (Top1) Inhibitor Payload for Telisotuzumab Adizutecan', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'Unconjugated Top1 inhibitor payload for telisotuzumab adizutecan.'}, {'measure': 'Stage 1: Incidence of Anti-Drug Antibodies (ADAs) for Telisotuzumab Adizutecan', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'Incidence of anti-drug antibodies for telisotuzumab adizutecan.'}, {'measure': 'Stage 1: Neutralizing Anti-Drug Antibodies (nADAs) for Telisotuzumab Adizutecan', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'Neutralizing anti-drug antibodies for telisotuzumab adizutecan.'}, {'measure': 'Stage 2: Change from Baseline at C5D1 in Physical Functioning as Measured by the Physical Functioning Domain of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/Quality of Life (QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much).'}, {'measure': 'Stage 2: Change from Baseline at C7D1 (Standard of Care [SOC] Arm) in Physical Functioning as Measured by the Physical Functioning Domain of the EORTC QLQ-C30', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much).'}, {'measure': 'Stage 2: Change from Baseline at C5D1 in in Diarrhea as Measured by the Physical Functioning Domain of the EORTC QLQ-C30', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/Quality of Life (QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much).'}, {'measure': 'Stage 2: Change from Baseline at C7D1 (SOC Arm) in Diarrhea as Measured by the Physical Functioning Domain of the EORTC QLQ-C30', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much).'}, {'measure': 'Stage 2: Change from Baseline at C5D1 in in Global Health Status (GHS)/QoL as Measured by the Physical Functioning Domain of the EORTC QLQ-C30', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/Quality of Life (QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much).'}, {'measure': 'Stage 2: Change from Baseline at C7D1 (SOC Arm) in GHS/QoL as Measured by the Physical Functioning Domain of the EORTC QLQ-C30', 'timeFrame': 'Up to a Maximum of 4 Years', 'description': 'The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much).'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Metastatic Colorectal Cancer', 'Telisotuzumab Adizutecan', 'ABBV-400', 'Trifluridine', 'Tipiracil', 'LONSURF', 'Bevacizumab', 'AndroMETa-CRC-064'], 'conditions': ['Metastatic Colorectal Cancer']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.abbvieclinicaltrials.com/study/?id=M24-064', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused telisotuzumab adizutecan to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met protein above cutoff level refractory metastatic colorectal cancer (mCRC).\n\nTelisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants are put into treatment arms as part of 2 stages. Each treatment arm in stage 1 receives a different dose of telisotuzumab adizutecan. Each treatment arm in stage 2 receives the optimal dose of telisotuzumab adizutecan or LONSURF plus bevacizumab. Up to approximately 460 adult participants with c-Met protein above cutoff level refractory mCRC, will be enrolled in the study in approximately 160 sites in 15-20 countries.\n\nIn stage 1, participants will receive intravenously (IV) infused telisotuzumab adizutecan dose A or B. In stage 2, participants will receive the optimal dose of IV infused telisotuzumab adizutecan or the standard of care (SOC), LONSURF oral tablets plus IV infused bevacizumab. The total study duration will be approximately 4 years.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Life expectancy \\>= 12 weeks per investigator assessment.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 during the screening period prior to the first dose of the study drug.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.\n\nExclusion Criteria:\n\n* Prior systemic regimen containing c-MET targeting antibody/bispecific or Antibody Drug Conjugate (c-Met targeting Antibody Drug Conjugate \\[ADC\\]).\n* History of allergic reactions or hypersensitivity to bevacizumab or any of its excipients, or to compounds similar to trifluridine/tipiracil.\n* Active infection as noted in the protocol.'}, 'identificationModule': {'nctId': 'NCT06614192', 'briefTitle': 'A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer', 'organization': {'class': 'INDUSTRY', 'fullName': 'AbbVie'}, 'officialTitle': 'AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff', 'orgStudyIdInfo': {'id': 'M24-064'}, 'secondaryIdInfos': [{'id': '2024-512804-20-00', 'type': 'OTHER', 'domain': 'EU CT'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Stage 1: Telisotuzumab Adizutecan Dose A', 'description': 'Participants will receive telisotuzumab adizutecan dose A, as part of the approximately 4 year study duration.', 'interventionNames': ['Drug: Telisotuzumab Adizutecan']}, {'type': 'EXPERIMENTAL', 'label': 'Stage 1: Telisotuzumab Adizutecan Dose B', 'description': 'Participants will receive telisotuzumab adizutecan dose B, as part of the approximately 4 year study duration.', 'interventionNames': ['Drug: Telisotuzumab Adizutecan']}, {'type': 'EXPERIMENTAL', 'label': 'Stage 2: Telisotuzumab Adizutecan Optimal Dose', 'description': 'Participants will receive the optimal dose of telisotuzumab adizutecan, as part of the approximately 4 year study duration.', 'interventionNames': ['Drug: Telisotuzumab Adizutecan']}, {'type': 'EXPERIMENTAL', 'label': 'Stage 2: Standard of Care (SOC)', 'description': 'Participants will receive the SOC, as part of the approximately 4 year study duration.', 'interventionNames': ['Drug: Trifluridine/Tipiracil', 'Drug: Bevacizumab']}], 'interventions': [{'name': 'Telisotuzumab Adizutecan', 'type': 'DRUG', 'description': 'Intravenous (IV) Infusion', 'armGroupLabels': ['Stage 1: Telisotuzumab Adizutecan Dose A', 'Stage 1: Telisotuzumab Adizutecan Dose B', 'Stage 2: Telisotuzumab Adizutecan Optimal Dose']}, {'name': 'Trifluridine/Tipiracil', 'type': 'DRUG', 'otherNames': ['LONSURF'], 'description': 'Oral Tablet', 'armGroupLabels': ['Stage 2: Standard of Care (SOC)']}, {'name': 'Bevacizumab', 'type': 'DRUG', 'description': 'IV Infusion', 'armGroupLabels': ['Stage 2: Standard of Care (SOC)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '91010', 'city': 'Duarte', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'City of Hope National Medical Center /ID# 267875', 'geoPoint': {'lat': 34.13945, 'lon': -117.97729}}, {'zip': '92618', 'city': 'Irvine', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'City of Hope - Orange County Lennar Foundation Cancer Center /ID# 270655', 'geoPoint': {'lat': 33.66946, 'lon': -117.82311}}, {'zip': '90033', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'USC Norris Comprehensive Cancer Center /ID# 268131', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '80401', 'city': 'Golden', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Lutheran Medical Center- Cancer Centers of Colorado /ID# 268175', 'geoPoint': {'lat': 39.75554, 'lon': -105.2211}}, {'zip': '06510', 'city': 'New Haven', 'state': 'Connecticut', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Yale New Haven Hospital /ID# 269125', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '32803', 'city': 'Orlando', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'AdventHealth Orlando /ID# 267970', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '30322', 'city': 'Atlanta', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Winship Cancer Institute of Emory University /ID# 266884', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '83712', 'city': 'Boise', 'state': 'Idaho', 'status': 'RECRUITING', 'country': 'United States', 'facility': "St. Luke's Cancer Institute: Boise /ID# 268095", 'geoPoint': {'lat': 43.6135, 'lon': -116.20345}}, {'zip': '60611-2927', 'city': 'Chicago', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Northwestern Memorial Hospital /ID# 268610', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60521', 'city': 'Hinsdale', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Hope And Healing Cancer Services /ID# 268541', 'geoPoint': {'lat': 41.80086, 'lon': -87.93701}}, {'zip': '62702', 'city': 'Springfield', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Springfield Clinic - First /ID# 268666', 'geoPoint': {'lat': 39.80172, 'lon': -89.64371}}, {'zip': '46250', 'city': 'Indianapolis', 'state': 'Indiana', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Community Cancer Center North /ID# 267965', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '39401', 'city': 'Hattiesburg', 'state': 'Mississippi', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Hattiesburg Clinic /ID# 267860', 'geoPoint': {'lat': 31.32712, 'lon': -89.29034}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Washington University /ID# 267872', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '59102', 'city': 'Billings', 'state': 'Montana', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 268185', 'geoPoint': {'lat': 45.78329, 'lon': -108.50069}}, {'zip': '08901', 'city': 'New Brunswick', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Rutgers Cancer Institute of New Jersey /ID# 268056', 'geoPoint': {'lat': 40.48622, 'lon': -74.45182}}, {'zip': '27514', 'city': 'Chapel Hill', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of North Carolina Medical Center /ID# 266879', 'geoPoint': {'lat': 35.9132, 'lon': -79.05584}}, {'zip': '27710', 'city': 'Durham', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Duke University Medical Center /ID# 267966', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'zip': '57105', 'city': 'Sioux Falls', 'state': 'South Dakota', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Avera Cancer Institute - Sioux Falls /ID# 268074', 'geoPoint': {'lat': 43.54369, 'lon': -96.72796}}, {'zip': '38138', 'city': 'Germantown', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'West Cancer Center and Research Institute - Germantown /ID# 268619', 'geoPoint': {'lat': 35.08676, 'lon': -89.81009}}, {'zip': '75235', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Texas - Southwestern Medical Center /ID# 268241', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'The University of Texas MD Anderson Cancer Center /ID# 268098', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77090', 'city': 'Houston', 'state': 'Texas', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Millennium Research & Clinical Development /ID# 268400', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '22908', 'city': 'Charlottesville', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Virginia /ID# 268108', 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}, {'zip': '4101', 'city': 'South Brisbane', 'state': 'Queensland', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Mater Hospital Brisbane /ID# 268360', 'geoPoint': {'lat': -27.48034, 'lon': 153.02049}}, {'zip': '5265601', 'city': 'Ramat Gan', 'state': 'Tel Aviv', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'The Chaim Sheba Medical Center /ID# 267741', 'geoPoint': {'lat': 32.08227, 'lon': 34.81065}}, {'zip': '6423906', 'city': 'Tel Aviv', 'state': 'Tel Aviv', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Tel Aviv Sourasky Medical Center /ID# 267578', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '3525408', 'city': 'Haifa', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Rambam Health Care Campus /ID# 267739', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '91120', 'city': 'Jerusalem', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Hadassah Medical Center-Hebrew University /ID# 267579', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '4941492', 'city': 'Petah Tikva', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Rabin Medical Center /ID# 267740', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'zip': '6789140', 'city': 'Tel Aviv', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Assuta Medical Center /ID# 267745', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '464-8681', 'city': 'Nagoya', 'state': 'Aichi-ken', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Aichi Cancer Center /ID# 268237', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'zip': '277-8577', 'city': 'Kashiwa-shi', 'state': 'Chiba', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'National Cancer Center Hospital East /ID# 268236'}, {'zip': '565-0871', 'city': 'Suita-shi', 'state': 'Osaka', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'The University of Osaka Hospital /ID# 268743'}, {'zip': '362-0806', 'city': 'Kitaadachi-gun', 'state': 'Saitama', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Saitama Prefectural Cancer Center /ID# 268706'}, {'zip': '104-0045', 'city': 'Chuo-Ku', 'state': 'Tokyo', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'National Cancer Center Hospital /ID# 268713'}, {'zip': '00935', 'city': 'Rio Piedras', 'status': 'RECRUITING', 'country': 'Puerto Rico', 'facility': 'Pan American Center for Oncology Trials /ID# 267888', 'geoPoint': {'lat': 18.39745, 'lon': -66.04989}}, {'zip': '13620', 'city': 'Seongnam-si', 'state': 'Gyeonggido', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Seoul National University Bundang Hospital /ID# 268592', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}}, {'zip': '03080', 'city': 'Seoul', 'state': 'Seoul Teugbyeolsi', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Seoul National University Hospital /ID# 268719', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '03722', 'city': 'Seoul', 'state': 'Seoul Teugbyeolsi', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Yonsei University Health System Severance Hospital /ID# 268718', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05505', 'city': 'Seoul', 'state': 'Seoul Teugbyeolsi', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Asan Medical Center /ID# 268717', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '06351', 'city': 'Seoul', 'state': 'Seoul Teugbyeolsi', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Samsung Medical Center /ID# 268720', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '833', 'city': 'Kaohsiung City', 'state': 'Kaohsiung', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'Kaohsiung Chang Gung Memorial Hospital /ID# 267638', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '100', 'city': 'Taipei City', 'state': 'Taipei', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'National Taiwan University Hospital /ID# 267627'}, {'zip': '50006', 'city': 'Changhua City, Changhua County', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'Changhua Christian Hospital /ID# 270464', 'geoPoint': {'lat': 24.0692, 'lon': 120.5512}}, {'zip': '807', 'city': 'Kaohsiung City', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 267635', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '404', 'city': 'Taichung', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'China Medical University Hospital /ID# 267631', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '407', 'city': 'Taichung', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'Taichung Veterans General Hospital /ID# 270467', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '704', 'city': 'Tainan', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'National Cheng Kung University Hospital /ID# 270468', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'zip': '112', 'city': 'Taipei', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'Taipei Veterans General Hospital /ID# 267628', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '333', 'city': 'Taoyuan', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'Linkou Chang Gung Memorial Hospital /ID# 267637', 'geoPoint': {'lat': 24.99368, 'lon': 121.29696}}], 'centralContacts': [{'name': 'ABBVIE CALL CENTER', 'role': 'CONTACT', 'email': 'abbvieclinicaltrials@abbvie.com', 'phone': '844-663-3742'}], 'overallOfficials': [{'name': 'ABBVIE INC.', 'role': 'STUDY_DIRECTOR', 'affiliation': 'AbbVie'}]}, 'ipdSharingStatementModule': {'url': 'https://vivli.org/ourmember/abbvie/', 'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'timeFrame': 'For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/', 'ipdSharing': 'YES', 'description': 'AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.', 'accessCriteria': 'To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AbbVie', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}